LTIP227A - Nauji farmakologiškai aktyvūs katecholio dariniai - Google Patents

Nauji farmakologiškai aktyvūs katecholio dariniai

Info

Publication number
LTIP227A
LTIP227A LTIP227A LTIP227A LTIP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A
Authority
LT
Lithuania
Prior art keywords
pharmacologically active
catechol derivatives
new pharmacologically
active catechol
new
Prior art date
Application number
LTIP227A
Other languages
English (en)
Inventor
Johannes Reijo Backstrom
Erkki Honkanen
Britt Inge LINDEN
Aarne Olavi Erkki NISSINEN
Aino Pippuri
Pentti Pohto
Tapio Korkolainen
Original Assignee
Orion-Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909009565A external-priority patent/GB9009565D0/en
Priority claimed from GB919101563A external-priority patent/GB9101563D0/en
Application filed by Orion-Yhtymae Oy filed Critical Orion-Yhtymae Oy
Publication of LTIP227A publication Critical patent/LTIP227A/lt
Publication of LT3137B publication Critical patent/LT3137B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulę (1) atitinkantys katecholio junginiai, kurioje R1 reiškia tokį elektriškai neigiamą pakaitą, kaip nitro-, halogeno ar ciano-grupė, o R2 yra grupė, pasirinkta iš (1a) ir (1b), kur R reiškia vandenilį arba alkilo, cikloalkilo ar arilo grupę, kurioje X1, X2, Y ir Z nepriklausomai reiškia deguonį ar sierą, priklausančius NR, kur R gali turėti aukščiau nurodytas reikšmes ir farmaciškai priimtinos jų druskos bei esterai, naudingi dėl lipidų peroksidacijos atsiradusio audinių pakenkimo profilaktikai ir gydymui.
LTIP227A 1990-04-27 1992-11-17 New pharmacologically active catechol derivatives LT3137B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909009565A GB9009565D0 (en) 1990-04-27 1990-04-27 New pharmacologically active catechol derivatives
GB919101563A GB9101563D0 (en) 1991-01-24 1991-01-24 New pharmacologically active catechol derivatives
PCT/FI1991/000124 WO1991017151A1 (en) 1990-04-27 1991-04-26 New pharmacologically active catechol derivatives

Publications (2)

Publication Number Publication Date
LTIP227A true LTIP227A (lt) 1994-08-25
LT3137B LT3137B (en) 1995-01-31

Family

ID=26297011

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP227A LT3137B (en) 1990-04-27 1992-11-17 New pharmacologically active catechol derivatives

Country Status (17)

Country Link
US (3) US5362733A (lt)
EP (1) EP0526598B1 (lt)
JP (1) JP2972377B2 (lt)
KR (1) KR100207144B1 (lt)
AT (1) ATE146462T1 (lt)
AU (1) AU646464B2 (lt)
CA (1) CA2080917C (lt)
DE (1) DE69123738T2 (lt)
FI (1) FI95129C (lt)
HU (1) HU214872B (lt)
IE (1) IE911430A1 (lt)
LT (1) LT3137B (lt)
LV (1) LV10097B (lt)
NO (1) NO301928B1 (lt)
PL (1) PL166269B1 (lt)
PT (1) PT97507B (lt)
WO (1) WO1991017151A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10512883A (ja) * 1995-01-23 1998-12-08 イーライ・リリー・アンド・カンパニー 多発性硬化症の治療方法
WO1998033777A1 (en) * 1997-01-31 1998-08-06 Shionogi & Co., Ltd. Compounds having metalloprotease inhibitory activity
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU7961800A (en) * 1999-10-28 2001-05-08 Kyowa Hakko Kogyo Co. Ltd. Thiazolidinedione derivatives
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
MXPA04000695A (es) * 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
US6679051B1 (en) * 2002-07-31 2004-01-20 Ford Global Technologies, Llc Diesel engine system for use with emission control device
DK1689726T3 (da) 2003-11-21 2010-12-06 Actelion Pharmaceuticals Ltd 5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midler
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US7872027B2 (en) * 2006-02-17 2011-01-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Low molecular weight Myc-max inhibitors
JP4669564B2 (ja) * 2006-11-23 2011-04-13 アクテリオン ファーマシューティカルズ リミテッド ２−イミノ−チアゾリジン−４−オン誘導体の製造のための新規な方法
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
CA2734991A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
HRP20190249T1 (hr) 2011-07-22 2019-04-05 Massachusetts Institute Of Technology Aktivatori razreda i histonskih deacetilaza (hdacs) i njihova uporaba
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
EP3439667B1 (en) 2016-04-05 2024-01-03 Immune Sensor, LLC Cgas antagonist compounds
WO2022163843A1 (ja) * 2021-02-01 2022-08-04 国立大学法人徳島大学 Ｐｉｍ２阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
GB1434074A (en) * 1972-06-16 1976-04-28 Canada Packers Ltd Antiviral compositions comprising hydantoin derivatives
US4013770A (en) * 1972-06-16 1977-03-22 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
US4264617A (en) * 1972-06-16 1981-04-28 Canada Packers, Limited Antiviral 5-(substituted benzal) hydantoins
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
DE3013626C2 (de) * 1980-04-09 1985-06-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (A)
DE3013647C2 (de) * 1980-04-09 1985-07-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (B)
JPS60233063A (ja) * 1984-05-02 1985-11-19 Showa Denko Kk ５−ベンジリデンヒダントインの製造法
US4650876A (en) * 1984-08-17 1987-03-17 Stauffer Chemical Company Hydrogenation of substituted, unsaturated hydantoins to substituted, saturated hydantoins
US4582903A (en) * 1984-08-17 1986-04-15 Stauffer Chemical Company Synthesis of unsaturated hydantoins with an inexpensive catalyst
IL79648A (en) * 1985-08-09 1991-12-12 Lilly Co Eli Pharmaceutical anti-inflammatory and ischemia preventing compositions containing di-t-butylphenol derivatives,some such novel compounds and process for their preparation
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
GB8911073D0 (en) * 1989-05-15 1989-06-28 Fujisawa Pharmaceutical Co New benzofuran derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
JPH1052765A (ja) 1996-08-09 1998-02-24 Sukematsu Iwashita 鉄筋材の圧接装置

Also Published As

Publication number Publication date
NO924132L (no) 1992-12-23
PL166269B1 (pl) 1995-04-28
CA2080917A1 (en) 1991-10-28
HU9203369D0 (en) 1993-01-28
WO1991017151A1 (en) 1991-11-14
LT3137B (en) 1995-01-31
LV10097B (en) 1995-02-20
LV10097A (lv) 1994-05-10
FI924838A0 (fi) 1992-10-23
PT97507B (pt) 1998-08-31
DE69123738T2 (de) 1997-07-03
AU7761891A (en) 1991-11-27
NO301928B1 (no) 1997-12-29
FI95129C (fi) 1995-12-27
PT97507A (pt) 1992-01-31
KR930700468A (ko) 1993-03-15
NO924132D0 (no) 1992-10-26
US5614541A (en) 1997-03-25
DE69123738D1 (en) 1997-01-30
US5889037A (en) 1999-03-30
AU646464B2 (en) 1994-02-24
HU214872B (hu) 1998-07-28
HUT65662A (en) 1994-07-28
JP2972377B2 (ja) 1999-11-08
CA2080917C (en) 2001-06-12
IE911430A1 (en) 1991-11-06
JPH05331148A (ja) 1993-12-14
EP0526598B1 (en) 1996-12-18
FI95129B (fi) 1995-09-15
EP0526598A1 (en) 1993-02-10
FI924838A7 (fi) 1992-10-23
US5362733A (en) 1994-11-08
KR100207144B1 (en) 1999-07-15
ATE146462T1 (de) 1997-01-15

Similar Documents

Publication Publication Date Title
LTIP227A (lt) Nauji farmakologiškai aktyvūs katecholio dariniai
DE69433353D1 (de) Bicyclische, heterocyclische sulfonamide und sulfonsäureester
AU2418188A (en) Therapeutic heterocyclic compounds
NO875240D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv morfolinoethylester av mycofenolsyre og derivater derav.
ES2194986T3 (es) Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
DE68924681D1 (de) Heterocyclische Biphosphonsäurederivate.
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
AU647904B2 (en) Novel nonsedative antihistaminics derived from benzimidazoles
RU95110762A (ru) Производные 5-гидразинохинолона, композиция для лечения или профилактики инфекционного заболевания, способ лечения или профилактики
FI914187A0 (fi) Menetelmä valmistaa kaavan /I/ mukaista 1-metyylikarbapeneemijohdosta
DE69725585D1 (de) Phenylalkylcarbonsäure-derivate
NO168243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
IS3828A (is) Hliðstæð aðferð til tilreiðslu á nýjum afleiðum thiazolidinone og oxazolidinone sem gagnlegar eru til æðaútvíkkunar
AU6731100A (en) Integrase inhibitors containing aromatic heterocycle derivatives
EP0878196A4 (en) INHIBITORS OF KAINIC ACID NEUROTOXICITY AND PYRIDOTHIAZINE DERIVATIVES
ES2158290T3 (es) Derivados de tiazolidinona opticamente activos.
NO972731L (no) Thiazolidinonforbindelser og terapeutisk eller forhindrende middel mot angina pectoris omfattende forbindelsene som aktiv bestanddel
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
EP1142868A4 (en) AMIDE DERIVATIVES
DE59006477D1 (de) Fünfring-heterocyclisch anellierte Chinolinderivate.
DK0471856T3 (da) 15-Deoxyprostaglandin-derivater
EP0314432A3 (en) Fungicidal pyridyl sulphenyl carbamates
NO20004679L (no) Farmasøytisk sammensetning inneholdende en cystein- proteasehemmer for forebygging og terapi av hjernevevsforringelse
AU6982994A (en) Benzene derivative useful for ischemic diseases

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20021117